Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label trial of eculizumab in adult patients with atypical hemolytic uremic syndrome
2010-020326-18Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS) and hemolytic uremic syndrome (HUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Complete TMA response. Started Aug 2010; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2010-020326-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020326-18.